G-protein-coupled receptors (GPCRs) represent one of the largest gene families in the human genome and have long been regarded as valuable targets for small-molecule drugs. The authors describe a new functional assay that directly monitors GPCR activation. It is based on the interaction between β-arrestin and ligand-activated GPCRs and uses enzyme fragment complementation technology. In this format, a GPCR of interest is fused to a small (~4 kDa), optimized α fragment peptide (termed ProLink™) derived from β-galactosidase, and β-arrestin is fused to an N-terminal deletion mutant of β-galactosidase (termed the enzyme acceptor [EA]). Upon activation of the receptor, the β-arrestin-EA fusion protein binds the activated GPCR. This interaction drives enzyme fragment complementation, resulting in an active β-galactosidase enzyme, and thus GPCR activation can be determined by quantifying β-galactosidase activity. In this report, the authors demonstrate the utility of this technology to monitor GPCR activation and validate the approach using a Gα i -coupled GPCR, somatostatin receptor 2. Potential application to high-throughput screens in both agonist and antagonist screening modes is exemplified. (Journal of Biomolecular Screening 2008:737-747) 
INTRODUCTION

G
-PROTEIN-COUPLED RECEPTORS (GPCRS), Characterized by 7 transmembrane domains and heterotrimeric G-protein coupling, play important roles in diverse cellular and physiological functions, including light sensing, smell, appetite control, insulin secretion, and blood pressure modulation. 1 Sequencing of the human genome revealed that GPCRs constitute the largest family of cell surface receptors, with more than 720 members. 2, 3 GPCRs have historically proved to be the most tractable targets for small-molecule drug discovery: 27% of the drug targets for all marketed medicines are GPCRs, 4 and 9 of the top 20 small-molecule drugs target GPCRs. 5 Agonist binding of GPCRs leads to conformational changes in the receptor and increased association with G-protein heterotrimers. In this complex, the G-protein α-subunit adopts a conformation with high affinity for guanosine 5′-triphosphate (GTP). Subsequently, α-and βγ-subunits separate and dissociate from the receptor to interact with and regulate distinct effectors, leading to changes in the levels of intracellular second messengers: Gα s activates adenylyl cyclase activity, subsequently resulting in increased cellular cyclic adenosine monophosphate (cAMP) levels. Conversely, Gα i inhibits adenylyl cyclase activity, leading to decreased cellular cAMP levels. Gα q , as well as promiscuous Gα 15/16 subunits, activates phospholipase C, increasing cytoplasmic Ca ++ levels as Ca ++ is released from intracellular stores. Binding of an agonist to a GPCR not only initiates intracellular signaling cascades but also triggers desensitization, which protects cells from overstimulation. 6 Following activation by its cognate agonist, the cytoplasmic C-terminal tail of the GPCR becomes phosphorylated by G-protein-coupled receptor kinases (GRKs). Subsequently, β-arrestins translocate to and bind the phosphorylated receptor in juxtaposition, located at the cytoplasmic membrane. β-Arrestin binding sterically hinders the receptor from activating additional G-proteins, thereby terminating or "arresting" the receptor response. β-Arrestins consequently result in targeting of the receptor to clathrin-coated pits for endocytosis.
Once internalized, GPCRs are either recycled back to the cell surface or degraded within the cell. 7, 8 Among the functional cell-based assays for GPCRs currently available (see Xiao et al. 9 and Eglen et al. 5 for review), β-arrestin translocation assays offer a novel means by which to monitor and assay GPCRs when there is no need for a priori knowledge of any agonist-induced signaling cascade. 6, 10 There are reports of a number of assay technologies that use β-arrestin translocation as a surrogate for receptor activation. Transfluor ® technology employs a β-arrestin fusion with green fluorescent protein (GFP) and uses high-content screening instrumentation to monitor protein redistribution. 11 However, the robustness of this approach is limited due to relatively low increases in local fluorescence and high cell-to-cell variability, hindering the application of this method for higher throughput primary screening. A second β-arrestin redistribution-based technology, Invitrogen's Tango™, reads out spatial redistribution using a quantifiable reporter assay employing a protease-tagged β-arrestin and a GPCR-transcription factor fusion. Upon activation, the protease is recruited to the membrane-located receptor, where it acts on the receptor construct to liberate a transcription factor and thus initiate reporter gene expression. 12 This can be readily detected to read out receptor activation.
Here we describe a new assay system that uses β-galactosidase enzyme fragment complementation (EFC) 13 to monitor β-arrestin translocation (Fig. 1) . Enzyme fragment complementation comprises the association of 2 inactive enzyme fragments to reconstitute enzyme activity. A mutated amino-terminal fragment of β-galactosidase ProLink™ is fused to the carboxyl-terminus of GPCR, and an N-terminal deletion mutant similar to the M15 deletion mutant of β-galactosidase (EA) is fused to the C-terminus of the β-arrestin molecule. 14, 15 In cells stably expressing these fusion proteins, ligand stimulation triggers association between the β-arrestin and activated GPCR, driving complementation of the β-galactosidase fragments and enabling easy detection using various β-galactosidase substrates, including luminogenic ones. This technology eliminates any need for downstream reporter expression and offers the dual advantages of quantifiable signal generation and a receptor "proximal" readout without the need for high-content image analysis.
Somatostatin is a cyclic peptide widely expressed throughout the central nervous system, endocrine tissues, and gastrointestinal tract. It exists as 2 isoforms of either 28 or 14 amino acid residues. The 14-amino acid peptide, SST14, was first identified and isolated as a potent inhibitor of growth hormone release from the pituitary. 16, 17 Somatostatin exerts a wide range of biological actions, including inhibiting the secretion of growth hormone, insulin, glucagon, and gastrin, as well as other hormones secreted by the pituitary and gastrointestinal tract. 17 There are 5 known receptors for somatostatin. Among them, SSTR2 has been demonstrated to be the major player in this family, exerting broad inhibitory effects on both endocrine and exocrine secretion. It has been demonstrated that SSTR2 is coupled to the pertussis toxin-sensitive Gα i proteins. 18 In addition, SSTR2 belongs to the class of GPCRs that, when activated, form stable complexes with β-arrestins such that the receptor β-arrestin complex internalizes as a unit into early endosomes. 19, 20 In this report, the novel high-throughput assay (HCA) format that exploits β-arrestin translocation and enzyme fragment complementation 21 is evaluated for its utility in high-throughput screening (HTS) of the G i -coupled receptor SSTR2 in 384-and 1536-well formats. The assay resulted in excellent assay performance and pharmacology consistent with literature reports using traditional techniques.
MATERIALS AND METHODS
Materials
Peptides somatostatin 28 and somatostatin 14 were purchased from AnaSpec (San Jose, CA). Octreotate, seglitide, and CYN 154806 were purchased from Sigma (St. Louis, MO). White, tissue culture (TC)-treated, opaque-bottom, 384-well CulturePlates were purchased from PerkinElmer (Waltham, MA). Sterile universal lids were purchased from Nunc (New York), and 30% bovine serum albumin (BSA) was purchased from EMD Biosciences (San Diego, CA). Dulbecco's minimal essential medium (DMEM)/F12 50/50, geneticin, hygromycin B, 0.25% trypsin-EDTA, 1M HEPES, 200 mM L-glutamine, Dulbecco's phosphate-buffered saline, and 10,000-IU/mL penicillin/ 10,000-μg/mL streptomycin solution were purchased from Cellgro (Manassas, VA). Fetal bovine serum (FBS), trypsin, and Hank's buffered salt solution (HBSS) were purchased from Gibco
FIG. 1. Diagram of the PathHunter
® assay format: a G-protein-coupled receptor (GPCR) is tagged with ProLink™ at the C-terminus. Upon ligand binding, the ProLink™-tagged GPCR undergoes conformational change followed by G-protein-coupled receptor kinase (GRK) phosphorylation, resulting in recruitment of an enzyme acceptor (EA)-fused β-arrestin molecule. Binding initiates β-galactosidase fragment complementation, which forms an active enzyme that turns over substrate to generate a readily detectable chemiluminescent signal.
(Carlsbad, CA). Hygromycin B was purchased from HyClone (Logan, UT). TC-treated flasks (T175) were purchased from Nunc. PathHunter ® detection reagent was purchased from DiscoveRx (Fremont, CA), and 100% DMSO was purchased from Burdick & Jackson (Muskegon, MI).
Cell culture
The stable β-arrestin cell line, SSTR2 PathHunter ® CHOK1, was maintained in adherent culture at subconfluent densities in T-175 TC-treated flasks with growth media containing DMEM/F12, 10% fetal bovine serum, 1% penicillin-streptomycin, 1% L-glutamine, and selection reagents geneticin (400 μg/mL) and hygromycin B (400 μg/mL).
PathHunter
® ® assay procedure
One day prior to assay, cells were harvested with trypsin and resuspended in media containing 0.5% FBS. CulturePlates (PerkinElmer) were seeded with 5000 cells in 20 μL of culture medium unless otherwise indicated. Plates were lidded and incubated overnight at 37 °C with 5% CO 2 .
On the day of the assay, 5 μL of peptide in buffer (1X HBSS with 20 mM HEPES and 0.01% BSA) was added to the wells of a 384-well plate at the indicated concentration. Plates were incubated 90 min at room temperature or at 37 °C in a tissue culture incubator as indicated, followed by addition of 12 μL PathHunter ® detection mix, prepared according to the manufacturer's instructions. The luminescent signal was detected 60 min after the substrate addition by reading 384-well plates on an EnVision™ multimode reader (PerkinElmer) using 0.2-s/well integration time.
For 1536-well plates, cells were suspended in assay buffer (1X HBSS with 20 mM HEPES and 0.01% BSA). Then, 3 μL cells were seeded into assay plates containing 3 μL of compounds or peptides immediately followed by cell induction. No overnight cell attachment was required in this assay. After incubation, 3 μL of PathHunter ® detection mix was added. The 1536-well plates were read using a Viewlux™ (PerkinElmer) using a 20-s integration time for the whole plate. cAMP assay cAMP levels were measured using the cAMP-Screen Direct System™ from Applied Biosystems (Foster City, CA). Ten thousand cells, suspended in 8 μL of media, were seeded into each well of the 384-well assay plates provided with the assay kits. A 2-μL mixture of forskolin and ligand peptide was added to the cells to make a 16-μM final concentration. The plate was incubated at 37 °C for 45 min, and 10 μL of cell lysis buffer was added. cAMP levels were then detected according to the manufacturer's instructions. A cAMP standard curve was generated in parallel and used to calibrate the assay. β β-Arrestin immunostaining and analysis using Opera™ ™ instrument Cells were grown overnight on coverslips in complete culture medium. The following day, they were transferred to 6-well plates containing fresh media and equilibrated in a 37 °C incubator for 30 min. Cells were treated with SST28 peptide for 1 h at the concentrations indicated and media rapidly removed by aspiration. Cells were fixed using 3.7% formaldehyde in phosphate-buffered saline (PBS) for 15 to 20 min at room temperature followed by washing Grove, PA; 1:400 in Blotto), was added. Cells were incubated at room temperature for 20 min in the dark, followed by 3 washes with 1X PBS. Coverslips were mounted using antifade solution (VectaShield with DAPI from Vector Labs, Burlingame, CA). Immunofluorescence microscopy was performed using a standard epifluorescence microscope.
For quantitative translocation assays, cells were cultured in 96-well black, clear-bottomed plates and immunostaining conducted as described earlier. The plate was read using an Opera™ (Evotec, Hamburg, Germany).
HTS and data analysis
Cells were counted using the Guava ® Personal Cell Analysis system (Guava Technologies, Hayward, CA) and dispensed with Titan 384-well Multidrops ® (Titertek, Huntsville, AL). Vprep ® and Benchcel ® robots (Velocity11, Menlo Park, CA) were used to make peptide additions when assaying for agonists. A FlexDrop™ (PerkinElmer) was used in combination with the Benchcell robot (Velocity11) to dispense agonist peptide during the antagonist assay. The WellMate ® (Matrix, Hudson, NH) was used for bulk-dispensing substrate. Plates were read on EnVision™ multimode reader (PerkinElmer).
Experimental data were normalized as a percentage of positive control (POC) using DMSO (0% POC) as a baseline and 10 nM SST28 as 100% POC. In the agonist assay, a hit was defined as any compound with activity ≥50% POC. For the antagonist assay, a hit was defined as any compound with activity ≤ 50% POC. Z′ values were calculated according to Zhang et al. 22 using the following
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formula: Z′ = 1 -3* (SD positive + SD negative)/(mean positivemean negative). Z′ values between 0.5 and 1 were interpreted as evidence of an excellent assay suitable for HTS.
RESULTS
Generation of SSTR2-PathHunter ® ® stable cell lines
PathHunter ® GPCR/β-arrestin cell lines were generated from a clonally derived parental Chinese hamster ovary (CHO) cell line expressing human β-arrestin2 fused at the C-terminus to the EA fragment of β-galactosidase. The fusion construct was introduced using a murine Moloney leukemia virus (MMLV) retroviral expression system with a hygromycin selectable marker (Clontech, Mountain View, CA). Clonal cell lines were generated by limiting dilution techniques and analyzed for homogeneity by immunofluorescence using an antibody to the EA protein (DiscoveRx). Human SSTR2 cDNA (GenBank AY236542) was C-terminally fused to the ProLink™ peptide fragment of β-galactosidase using a commercially available cloning vector that includes a neomycin selectable marker (DiscoveRx). This fusion protein was then subcloned into an MMLV retroviral vector carrying a neomycin selection marker, and the CHO arrestin parental cell line was infected with virus using standard techniques. Clonal cell lines expressing both the SSTR2 GPCR and the human β-arrestin2 were generated using double antibiotic selection and limiting dilution cloning. Clonal cell lines were analyzed for functional responses to agonist and passage stability out to 20 passages.
SSTR2 pharmacology analysis
To verify that the receptor-Prolink™ and β-arrestin-EA constructs retain signaling competence and exhibit pharmacology consistent with naturally occurring proteins, we tested 4 known SSTR2 agonists in the PathHunter ® SSTR2 CHO stable cell line. All 4 agonists-SST28, SST14, octreotate, and seglitideshowed similar maximum efficacy (Fig. 2) and large assay windows (>30-fold signal increase over basal level). More important, derived EC 50 values (2.40 nM, 0.33 nM, 0.24 nM, and 0.63 nM, respectively) were consistent with literature values ( Table 1 ) obtained using a cAMP assay, 23 GTG-g-S binding assay, 24 and competition ligand binding assay. 25 To better understand the kinetics of β-arrestin translocation, we evaluated agonist treatment duration and temperature to identify an optimal time window for agonist induction. At room temperature, signal increased with increasing induction time (Fig. 3A) , and a response could be seen at the shorted time point tested (15 min). The signal started to saturate after 60 min, peaked at 120 min, and was stable for at least 3 h. The EC 50 shifted slightly with time, from 5.7 nM after a 15-min agonist induction to 2.6 nM after a 180-min induction. Treatment at 37 °C (Fig. 3B) showed faster kinetics, and the signal peaked earlier at 60 min. Observed EC 50 s again shifted slightly with time, from 5.8 nM (at 15 min) to 3.1 nM (at 180 min).
The PathHunter
® technology depends on complementation between ProLink™ and EA to form active β-galactosidase to generate signals, and thus the signal increase may be affected by changes in ProLink™ or EA expression levels during the assay. However, this is not the case because no significant differences were observed in the presence of cycloheximide, a known protein synthesis inhibitor (data not shown), suggesting that signal generation is due to protein translocation and independent of new protein synthesis.
One of the postulated advantages of the PathHunter ® assay is that it is receptor proximal, rather than downstream, of specific G-protein activation. Therefore, it is not subject to falsepositive hits resulting from "off-target" inhibition of downstream signaling elements. This was demonstrated using pertussis toxin, a known Gα i protein inactivator that was tested for its effect on the assay. Results (data not shown) indicate that it has no effect, confirming our hypothesis that the PathHunter To further verify the pharmacology of the SSTR2-ProLink™ fusion, we tested the potency of SST28 using a conventional cAMP assay to measure decreases in cellular cAMP levels. As shown in Figure 4B , agonist treatment resulted in a 2-fold reduction of cAMP levels with an EC 50 of 0.2 nM. This result is consistent with that reported from endogenous expressed SSTR2 in AtT-20 cells. 16 However, the induction window was much smaller than the 30-fold effect obtained with the PathHunter ® assay, making HTS with the cAMP assay unfeasible for this target. The consistency of this pharmacology indicates that, at least for the SSTR2 receptor, the fusion of ProLink™ to the C-terminus of the receptor does not adversely affect the GPCR signaling response.
To further characterize the PathHunter ® assay, we monitored β-arrestin translocation using fluorescent immunostaining and high-content screening (HCS) analysis techniques. Prior to SST28 treatment, β-arrestin was evenly distributed in the cytosol (Fig. 4A) . Upon agonist stimulation, internalization vesicles were clearly apparent (Fig. 4A, panels b-d) in numbers that correlated with agonist dosage. Translocation of the β-arrestin-EA fusion was quantified using Opera™ HCS analysis software to determine average vesicle intensity over a defined area. This parameter was used to assess receptor activation. An 8-fold increase in vesicle formation was achieved using SST28 ligand peptide, yielding an EC 50 of 11.4 nM (Fig. 4C) . The EC 50 obtained from the PathHunter ® assay falls between the values obtained using the cAMP assay and immunostaining HCS, further demonstrating that the pharmacology of the PathHunter ® assay is broadly consistent with previously validated approaches.
384-Well HTS of SSTR2 in PathHunter
® ® format
After examining the pharmacology of the SSTR2-ProLink™ in the cells expressing β-arrestin-EA fusion, we next asked whether this assay technology was suitable for HTS. Small-molecule compound libraries are typically predissolved in DMSO and stored until required, when they are diluted and subsequently applied to cells during screening. Thus, we determined the tolerance of the assay, including the cells, to DMSO. Concentrations of 0%, 1%, 2%, and 4% DMSO were tested for their effects on the assay. Although DMSO treatment resulted in a slight decrease in overall signal (Fig. 5A) , no significant changes in EC 50 were observed. Although there was a reduction in the assay window at 4% DMSO, it remained greater than 30-fold. This indicates that the cells can tolerate up to 4% DMSO, although the subsequent validation work was carried out using 2% DMSO.
A library of more than 30,000 small-molecule compounds was screened in a 384-well format using the optimized assay in agonist mode. A screen of 105 plates (Fig. 5B) yielded Z′ factors ranging from 0.5 to 0.85, which we interpreted as indicative of excellent assay performance. 22 However, no hits were obtained (Fig. 5C) . This was not totally unexpected in light of our previous experience, which has shown it to be relatively difficult to identify small-molecule agonists for peptide receptors.
Next, we developed and executed HTS in antagonist mode. To this end, we tested the response of the SSTR2-PathHunter ® cells to CYN 154806, a known SSTR2 antagonist. As shown in Figure 6A , CYN 154806 completely inhibited SST28-elicited β-arrestin translocation with an IC 50 of 181 nM. Based on the EC 50 of SST28, the pKB of CYN 154806 was calculated to be 8.1, consistent with literature reports using cAMP assays. 16 Subsequently, more than 30,000 compounds were screened in antagonist mode in the presence of 10 nM SST28. Z′ factors obtained from 104 plates (Fig. 6B) ranged from 0.50 to 0.85, again indicative of excellent assay performance. In contrast to the agonist screen, 98 hits were identified using <50% POC as a cutoff, with a hit rate of 0.29% and a compound concentration of 10 μM (Fig. 6C) . . After a 90-min incubation, the cells were fixed and stained as described previously. Images were collected using an epifluorescent microscope. (B) Cyclic adenosine monophosphate (cAMP) assay of SSTR2 PathHunter ® CHO cells: cells were treated with SST28 at the concentration indicated in the presence of 16 mM forskolin. After a 45-min incubation at 37 °C, the cells were lysed and cAMP levels determined using the Tropix cAMP screen kit. True cAMP levels were calculated from a cAMP standard curve generated in parallel. The data represent mean ± standard deviation (n = 3). (C) β-Arrestin translocation analysis: SSTR2 PathHunter ® CHO cells were seeded in 96-well, black, clear-bottomed plates and stimulated with SSTR28 peptide at the concentrations indicated. T cells were fixed and stained as described in the Materials and Methods section. The image was collected using the Evotec Opera™ and analyzed as described. Translocation was calculated using the average vesicle intensity over area. The data represent the mean ± standard deviation (n = 8).
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and positive controls) were tested, and each yielded Z′ factors greater than 0.5 (Fig. 7B) , indicating that the assay was robust. 22 Furthermore, wells spiked with agonist peptide SST28 at EC 10 , EC 50 , and EC 90 concentrations were tested to evaluate the capability of the assay to identify hits ( Table 2 ). All the wells spiked with SST28 at EC 50 and EC 90 were readily identified as positive hits, and wells containing EC 10 concentrations of the agonist were also apparent, albeit with comparatively low separation, from negative control values as anticipated.
DISCUSSION
Traditionally, second-messenger detection or downstream transcription/translation monitoring has been used to detect the functional activities of GPCRs. However, successful application of such functional assays requires specific knowledge of GPCR signaling pathways. That is, there is a requirement for the GPCR to be coupled to a specific relevant form of the Gα protein that is not always known. Here we report a robust assay suitable for HTS that enables monitoring GPCR activation through β-arrestin translocation that is independent of any particular Gα protein.
β-Galactosidase enzyme fragment complementation technology has long been applied in the diagnostics and HTS field using chemically conjugated enzyme donor (ED) constructs in various homogeneous in vitro assay formats. 13 Established recombinant expression techniques enable facile terminal tagging of proteins with another form of the small peptide ED (called ProLabel) tag. Consequently, protein expression level changes can be readily quantified simply by supplementing cell lysates with EA to proportionally reconstitute β-galactosidase activity. 26 The recent description of a mutant ED peptide (designated ProLink™) with reduced affinity for the EA fragment has enabled extension of this technology to the monitoring of protein-protein interactions and protein translocation. Wehrman et al. 21 first described the utility of this approach for nuclear hormone receptor translocation studies, also demonstrating application to follow membrane translocation of a PH domain following protein kinase C (PKC) activation.
Here we have applied enzyme fragment complementation technology using ProLink™ to monitor β-arrestin translocation upon GPCR activation. The limitation of the technology is that we have to use an engineered receptor that has a C-terminal fusion. However, the pharmacology of 4 SSTR2 agonists and an antagonist thus determined is consistent with values from more established functional assays such as the cAMP assay used by Cervia et al., 16 showing that tagging of ProLink™ to the C-terminal of the SSTR2 receptor was not detrimental to receptor activation and that β-arrestin translocation correlates well with GPCR activation. In addition, readout was demonstrated to be due to β-arrestin translocation and not any irrelevant secondary effect such as changes in the expression levels of any of the assay components because protein synthesis inhibition had no effect on the values obtained.
A key advantage of β-arrestin translocation assays is their lack of dependence on specific G-proteins. This is supported by the demonstration that the SSTR2 assay was not affected by Gα i protein inhibition using pertussis toxin. This provides for broad application of the PathHunter ® assay platform to many different GPCRs coupled to disparate Gα proteins. Moreover, some GPCRs have been demonstrated to couple to multiple G-proteins and accordingly activate different signaling pathways dependent on the coupling partner. These interactions are likely to be affected by many complex factors such as cellular context. 27, 28 Consequently, researchers have historically been faced with the need to select a screening approach while possessing only incomplete or inadequate information about signaling pathways and second-messenger utilization. In many cases, β-arrestin translocation assays provide a means to avoid this dilemma. However, β-arrestin technology may not be universally applicable as there are reports of GPCRs that do not appear to associate with any known isoforms of β-arrestin. 29 Conversely, another group of receptors appears to associate constitutively with β-arrestin, and these also are likely to prove intractable using the approach described earlier. 30 The rate of β-arrestin translocation following SSTR2 activation in the PathHunter ® assay appears maximal within 15 min at 37 °C, whereas this does not occur until 30 min at room temperature. Interestingly, at 37 °C, the signal was maximal after 60 min and gradually decreased thereafter. These kinetics results appear to be consistent with internalization studies conducted using EGFP-tagged β-arrestin and image analysis systems. Tulipano et al. 19 reported that β-arrestin translocation was seen as rapidly as 5 min after treatment at 37 °C, with saturation occurring after ~50 min. After 30 min, the β-arrestin-EGFP/receptor complex begins to be detected in endosomes. The gradual signal decrease after 60 min is consistent with the time frame when the complex is expected to start appearing in the endosome where proteins are targeted for degradation and the breakdown of the β-arrestinreceptor complex is anticipated. Complementation kinetics of β-galactosidase has been reported to be maximal at 37 °C, with reduced complementation rates at lower temperatures. This is consistent with the slower kinetics shown here when induction takes place at room temperature.
We have demonstrated that PathHunter ® assays are robust and offer a large assay window. Plates screened in the SSTR2 assay described returned an average Z′ >0.6. Thus, PathHunter ® technology is well suited to HTS applications in both agonist and antagonist modes. Indeed, the application of the β-arrestin translocation assay in HTS or HCS has been reported previously. Transfluor ® (MDS, Sunnyvale, CA) 11,14 exploits GFPtagged β-arrestin to directly monitor β-arrestin translocation using imaging-based instruments and has seen widespread use across the industry. However, substantial expression of the fusion protein is necessary. This invites questions as to whether the physiological balance of proteins in the cells is adversely affected, skewing results. In addition, limited signal amplification constrains the degree of local fluorescence detectable upon protein translocation with the effect that assays may suffer from small detection windows and wide variability. Image collection and analysis requires specific instrumentation and software. Another assay technology dependent on β-arrestin translocation measurement is the Tango™ (Invitrogen, Carlsbad, CA). 12 In this assay, a signal amplification step is achieved through gene transcription and translation, using a reporter readout to quantify β-arrestin translocation. The amplified signal yields a relatively large assay window and provides good assay sensitivity to receptor activation. Yet, when used in HTS mode, this assay inherits the disadvantages of a traditional reporter assay such as high hit rates arising from potential off-target effects and the potential for false positives from cytotoxic effects of compounds magnified during a prolonged preincubation period.
In the PathHunter ® HTS experiments described earlier, extremely low hit rates were obtained. A major concern for all cell-based assays is off-target effects, which lead to false positives that are time-consuming to identify and characterize. In this respect, assays monitoring receptor proximal events offer a potential advantage over those measuring downstream effects. In addition, off-target effects arising from endogenous receptors also contribute to false-positive rates during screening. In this assay, because only ProLink™-tagged receptors elicit signals, complications arising from endogenous receptors are minimized or eliminated, substantially decreasing false positives.
The PathHunter ® assay described here complements other β-arrestin translocation-based assays for screening GPCRs and offers advantages for cell-based assays of Gα i -coupled receptors for HTS purposes. Historically, screening for Gα i -coupled receptor modulators using cell-based assays has proved either extremely challenging or prohibitive, and thus the advent of β-arrestin-dependent detection formats represents an advance in our ability to use this group of GPCRs in HTS mode.
